Inflammation resolution, neuroprotection, and brain repair to promote stroke recovery
炎症消解、神经保护和大脑修复以促进中风康复
基本信息
- 批准号:10261320
- 负责人:
- 金额:$ 40.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-15 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcuteAdoptive TransferAdultAnti-Inflammatory AgentsAutoimmuneB-LymphocytesBehavioralBrainBrain DiseasesBrain InfarctionBrain InjuriesCD3 AntigensCD8B1 geneCXCR3 geneCell Culture TechniquesCell SeparationCellsCerebral IschemiaCognitiveDataDeteriorationDevelopmentDiffusion Magnetic Resonance ImagingDiseaseDistalDoseEconomic BurdenElectron MicroscopyElectrophysiology (science)EncephalitisEnvironmentEpidermal Growth FactorFosteringFunctional disorderGenderGenesGenetic TranscriptionGenomicsHarvestHistologicHomeHomeostasisIL2RA geneIL2RB geneImaging DeviceImmuneImmune responseImmune systemImmunohistochemistryImmunomodulatorsImmunotherapeutic agentIn VitroInfarctionInfiltrationInflammationInflammatoryInjuryInterleukin-10IschemiaIschemic Brain InjuryIschemic StrokeLIF geneLIFR geneLeadLightLymphocyteMediatingMemoryMiddle Cerebral Artery OcclusionModelingMolecularMusNamesNervous System PhysiologyNeurologic DeficitPathway interactionsPerformancePhasePilot ProjectsPlayPopulationProductionRegulatory T-LymphocyteResearchResolutionRodent ModelRoleSignal TransductionSliceStrokeT cell therapyT memory cellT-Cell DepletionT-LymphocyteTestingTherapeuticTransforming Growth FactorsUp-Regulationagedbrain repairclinically relevantclinically translatablecytokinefunctional outcomesgray matterimmunoregulationimprovedin vivo Modelinjury recoveryinterestleukemia inhibitory factor receptormaleneuroinflammationneurological recoveryneuroprotectionneurorestorationnovelnovel therapeutic interventionpost strokereconstitutionstroke outcomestroke recoverystroke therapytreatment strategywhite matter
项目摘要
Accumulating evidence implicates inflammation and immune responses in the pathophysiology of
stroke. Immunomodulation has therefore emerged as a promising therapy for stroke. Regulatory
lymphocytes, including CD4+CD25+ regulatory T cells (CD4+ Treg) and IL-10+ regulatory B cells (Bregs) are
established modulators of immune responses in the injured brain. We recently discovered that another
specialized T cell subpopulation—the CD8+CD122+CD49dhigh regulatory T cell—is among the first to enter
the ischemic brain, even preceding the infiltration of CD4+ Tregs and Bregs. The primary function of CD8+
Tregs is to modulate the activities of other immune cells, especially effector T lymphocytes, and to maintain
immune homeostasis. We found that selective depletion of circulating CD8+ Tregs exacerbated brain injury
and functional outcomes at 3 and 7 days after stroke, and this could be reversed by the reconstitution of
CD8+ Tregs. These exciting results suggest that CD8+ Tregs are natural defenders against ischemic brain
injury. Further pilot studies discovered that: 1) CD8+ Treg-afforded early protection relies on their infiltration
into the ischemic brain, as CD8+ Tregs lacking the “brain targeting signal” CXCR3 do not infiltrate into the
ischemic brain and lose their capacity to reduce brain infarction in CD8+ Treg-depleted mice. 2) The
infiltrated CD8+ Tregs undergo genomic reprogramming upon brain infiltration and transcriptional
upregulation of a group of genes that possess inflammation-resolving and/or neurorestorative functions,
including the leukemia inhibitory factor (LIF) receptor and epidermal growth factor-like transforming growth
factor (ETGF). 3) Post-stroke adoptive transfer of CD8+ Tregs significantly reduces brain infarct, enhances
white matter integrity, and improves neurological functions up to 14d after tMCAO. 4) Adoptive transfer of
ETGF-deficient CD8+ Treg fails to protect against tMCAO. The current proposal will further explore the effects
of CD8+ Tregs in ischemic stroke and develop CD8+ Treg adoptive transfer as an immune therapeutic therapy
for stroke. The novel central hypothesis to be tested is that brain infiltration of CD8+ Tregs promotes
long-term neurological recovery after stroke through LIF/LIFR/ETGF-mediated neuroprotection, resolution of
neuroinflammation, and neurorestorative mechanisms. Three specific aims are proposed. Aim 1. Establish
post-stroke adoptive transfer of CD8+ Tregs as a clinically relevant treatment against acute ischemic brain
infarct. Aim 2. Test the hypothesis that post-stroke adoptive transfer of CD8+ Tregs promotes long-term
neurological recovery and neurorestoration after ischemic stroke. Aim 3. Test the hypothesis that
LIF/LIFR-mediated release of ETGF is essential for CD8+ Treg-afforded neuroprotection and
neurorestoration. This study will be the first to rigorously investigate the role of CD8+ Tregs in ischemic brain
injury. The results will improve our understanding of stroke immunomodulation and shed light on CD8+ Treg
transfer as a potential therapeutic strategy.
越来越多的证据表明炎症和免疫反应与疾病的病理生理学有关
中风。因此,免疫调节已成为一种有前景的中风治疗方法。监管
淋巴细胞,包括 CD4+CD25+ 调节性 T 细胞 (CD4+ Treg) 和 IL-10+ 调节性 B 细胞 (Breg)
在受伤的大脑中建立了免疫反应的调节剂。我们最近发现另一个
专门的 T 细胞亚群——CD8+CD122+CD49d 高调节性 T 细胞——是最先进入的细胞之一。
甚至在 CD4+ Tregs 和 Breg 浸润之前。 CD8+的主要功能
Tregs的作用是调节其他免疫细胞,特别是效应T淋巴细胞的活性,并维持
免疫稳态。我们发现循环 CD8+ Tregs 的选择性耗竭会加剧脑损伤
以及中风后 3 天和 7 天的功能结果,这可以通过重构
CD8+ Tregs。这些令人兴奋的结果表明 CD8+ Tregs 是对抗缺血性大脑的天然防御者
受伤。进一步的试点研究发现:1)CD8+ Treg 提供的早期保护依赖于它们的渗透
进入缺血大脑,因为缺乏“大脑靶向信号”CXCR3 的 CD8+ Tregs 不会渗透到缺血大脑中
CD8+ Treg 缺失的小鼠大脑缺血并失去减少脑梗塞的能力。 2) 的
浸润的 CD8+ Tregs 在大脑浸润和转录后经历基因组重编程
上调一组具有消炎和/或神经恢复功能的基因,
包括白血病抑制因子 (LIF) 受体和表皮生长因子样转化生长
因子(ETGF)。 3) 中风后 CD8+ Tregs 的过继转移显着减少脑梗塞,增强
白质完整性,并在 tMCAO 后 14 天内改善神经功能。 4) 过继转让
ETGF 缺陷的 CD8+ Treg 无法预防 tMCAO。目前的提案将进一步探讨其影响
CD8+ Treg 在缺血性中风中的作用,并开发 CD8+ Treg 过继转移作为免疫治疗疗法
对于中风。待测试的新中心假设是 CD8+ Tregs 的大脑浸润促进
通过 LIF/LIFR/ETGF 介导的神经保护作用实现中风后长期神经功能恢复,解决
神经炎症和神经恢复机制。提出了三个具体目标。目标 1. 建立
中风后 CD8+ Tregs 过继转移作为针对急性缺血性脑的临床相关治疗
梗塞。目标 2. 检验中风后 CD8+ Tregs 过继转移促进长期治疗的假设
缺血性中风后的神经恢复和神经恢复。目标 3. 检验假设
LIF/LIFR 介导的 ETGF 释放对于 CD8+ Treg 提供的神经保护和
神经恢复。这项研究将是第一个严格研究 CD8+ Tregs 在缺血性脑中的作用的研究
受伤。该结果将提高我们对中风免疫调节的理解,并为 CD8+ Treg 提供线索
转移作为一种潜在的治疗策略。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jun Chen其他文献
Corrosion wear characteristics of TC4, 316 stainless steel, and Monel K500 in artificial seawater
TC4、316不锈钢、蒙乃尔K500在人工海水中的腐蚀磨损特性
- DOI:
10.1039/c7ra03065g - 发表时间:
2017-04 - 期刊:
- 影响因子:3.9
- 作者:
Jun Chen - 通讯作者:
Jun Chen
Jun Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jun Chen', 18)}}的其他基金
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
- 批准号:
10696455 - 财政年份:2023
- 资助金额:
$ 40.83万 - 项目类别:
Adiponectin on cerebrovascular regulation in vascular cognitive impairment and dementia (VCID)
脂联素对血管性认知障碍和痴呆 (VCID) 的脑血管调节作用
- 批准号:
10542359 - 财政年份:2022
- 资助金额:
$ 40.83万 - 项目类别:
Activation of the RXR/PPARγ axis improves long-term outcomes after ischemic stroke in aged mice
RXR/PPARγ 轴的激活可改善老年小鼠缺血性中风后的长期结果
- 批准号:
10364171 - 财政年份:2022
- 资助金额:
$ 40.83万 - 项目类别:
Activation of the RXR/PPARγ axis improves long-term outcomes after ischemic stroke in aged mice
RXR/PPARγ 轴的激活可改善老年小鼠缺血性中风后的长期结果
- 批准号:
10609791 - 财政年份:2022
- 资助金额:
$ 40.83万 - 项目类别:
Methods for Analysis of Genomic Data with Auxiliary Information
具有辅助信息的基因组数据分析方法
- 批准号:
10188885 - 财政年份:2021
- 资助金额:
$ 40.83万 - 项目类别:
Methods for Analysis of Genomic Data with Auxiliary Information
具有辅助信息的基因组数据分析方法
- 批准号:
10415152 - 财政年份:2021
- 资助金额:
$ 40.83万 - 项目类别:
Inflammation resolution, neuroprotection, and brain repair to promote stroke recovery
炎症消解、神经保护和大脑修复以促进中风康复
- 批准号:
9471926 - 财政年份:2017
- 资助金额:
$ 40.83万 - 项目类别:
Inflammation resolution, neuroprotection, and brain repair to promote stroke recovery
炎症消解、神经保护和大脑修复以促进中风康复
- 批准号:
9697886 - 财政年份:2017
- 资助金额:
$ 40.83万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 40.83万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 40.83万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 40.83万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 40.83万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 40.83万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 40.83万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 40.83万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 40.83万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 40.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 40.83万 - 项目类别:
Operating Grants